Making an impact at ESMO23 in Madrid
Read more about Prof Georgina Long receiving the ESMO Women for Oncology Award 2023, and MIA's significant contribution to cancer research discussions during ESMO23 in Madrid.
Researchers confirm the link between balding and skin cancer
“Research into the genetic drivers of skin cancer is critical” - MIA Co-Medical Directors Prof Georgina Long AO and Prof Richard Scolyer are co-authors on this study into the link between male pattern baldness and skin cancer.
Melanoma science in race against brain cancer – National Press Club
MIA Co-Medical Directors address the National Press Club of Australia detailing world-first breakthroughs in applying melanoma science to Richard Scolyer’s brain cancer.
Cutaneous melanoma: a contemporary overview published in The Lancet
A contemporary overview of Cutaneous melanoma, co-authored by MIA, has been published in The Lancet, one of the world's leading medical journals.
Prof Richard Scolyer receives SMR Lifetime Achievement Award
This prestigious award from the 'Society for Melanoma Research' recognises the contribution Richard has made to global melanoma research over the course of his career.
Major advance for neoadjuvant treatment of melanoma
The PBAC recommends expanding current PBS listing for pembrolizumab immunotherapy to allow neoadjuvant (before surgery) treatment of resected stage IIIB-D melanoma.
MIA researchers share learnings on global stage at ASCO23
Read more about how the MIA team continues to play a leading role in pushing melanoma research boundaries at ASCO23, the world's leading clinical oncology conference.
Prof Richard Scolyer awarded IAP ‘Distinguished Pathologist’ Medal
Read more about why Prof Richard Scolyer AO received the IAP Distinguished Pathologist Medal and watch his inspiring acceptance speech.
Prof Richard Scolyer AO honoured with ASDP Founders’ Award
This is the highest award from the American Society of Dermatopathology, and recognises Prof Scolyer's significant contribution to the field of #dermatopathology.
Expanded PBS access to immunotherapy treatment
Combined immunotherapy ipilimumab and nivolumab is now available on the PBS for all advanced melanoma patients.